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Abstract
Background: Ixekizumab improves signs/symptoms of psoriatic arthritis (PsA). We present an integrated analysis of
baseline disease burden and post-baseline outcomes in ixekizumab-treated patients with enthesitis or dactylitis.
Methods: Data from SPIRIT-P1 and SPIRIT-P2 were integrated. Patients with PsA were randomized to 80-mg
ixekizumab every 4 weeks (IXEQ4W) or 2 weeks (IXEQ2W), after a 160-mg starting dose, or to placebo. Inadequate
responders at week 16 received rescue therapy. Among patients with baseline enthesitis (Leeds Enthesitis Index
[LEI] > 0) or dactylitis (Leeds Dactylitis Index-Basic [LDI-B] > 0), baseline characteristics and disease burden were
reported. At week 24, LEI and LDI-B (percentage of patients with resolution [LEI = 0, LDI-B = 0]) were assessed. In
pooled treatment groups, the impact of enthesitis or dactylitis resolution on health-related quality of life (HRQoL)
(EuroQol-5 Dimensions Visual Analogue Scale [EQ-5D VAS]), physical function (Health Assessment Questionnaire-
Disability Index [HAQ-DI]), and pain was assessed.
Results: The integrated analysis set comprised 679 patients; of these, 60% (n = 403 of 675) had baseline enthesitis
(LEI > 0) and 23% (n = 155 of 676) had baseline dactylitis (LDI > 0). At week 24, ixekizumab-treated patients experienced
significantly more resolution than placebo of enthesitis (39% IXEQ4W, 35% IXEQ2W, 21% placebo) and dactylitis
(78% IXEQ4W, 65% IXEQ2W, 24% placebo). Furthermore, at entheseal points measured by the LEI, ixekizumab-treated
patients had significantly higher resolution of enthesitis compared to placebo. At week 24, among all placebo- and
ixekizumab-treated patients, resolution of enthesitis was associated with improvements in function and HRQoL
whereas dactylitis resolution was associated with more limited improvements. The least squares mean HAQ-DI
improvements from baseline were − 0.44 and − 0.25 for patients who did/did not resolve enthesitis, and − 0.41 and
− 0.31 for patients who did/did not resolve dactylitis. EQ-5D VAS improvements were 12.3 and 5.8 for patients who
did/did not resolve enthesitis, and 10.8 and 9.8 for patients who did/did not resolve dactylitis.
Conclusions: Among patients with pre-existing enthesitis or dactylitis, IXEQ2W- and IXEQ4W-treatment resulted in
significant improvements in enthesitis and dactylitis. Enthesitis resolution was associated with improvements in
patients’ function, pain, and HRQoL.
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Background
Psoriatic arthritis (PsA) is a chronic, inflammatory mus-
culoskeletal disease that frequently affects multiple joints
in the peripheral and axial skeleton, with clinical and
radiological damage progressing over time [1, 2]. Clinical
features of PsA include enthesitis and dactylitis [1],
which were highlighted by the Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) as two of the six commonly accepted clinical
domains of PsA that should be considered in treatment
decisions [3]. Enthesitis (inflammation at tendon, liga-
ment, or joint capsule’s insertion sites into bone) may be
the primary lesion in the development of PsA and was
present in 24 to 83% of patients with PsA in various
clinical trials using different measures [4, 5]. Similarly,
dactylitis (inflammation of the whole digit) is reported to
be present in 32 to 48% of patients with PsA [6, 7]; fre-
quently, multiple digits are involved [8]. Real-world evi-
dence suggests that enthesitis and dactylitis are
associated with higher disease burden [9].
Biologic therapy for patients with active enthesitis
and/or dactylitis is effective and is now recommended
for patients who have not responded well to nonsteroi-
dal anti-inflammatories or corticosteroid injections [3,
10]. Ixekizumab is an anti-interleukin-17A (IL-17A) an-
tagonist that has recently been approved for the treat-
ment of active PsA [11–14]. Here, we present a post hoc
integrated analysis of SPIRIT-P1 [13] and SPIRIT-P2
[14] to describe the baseline disease burden of enthesitis
and dactylitis and outcomes in patients with enthesitis
and dactylitis.
Methods
Patients and clinical trials
Data were obtained from SPIRIT-P1 (NCT01695239)
and SPIRIT-P2 (NCT02349295) [13, 14]. These are ran-
domized, double-blind, placebo-controlled, phase 3 trials
involving patients with active PsA previously described
[13, 14]. Patients were randomized to subcutaneous injec-
tions of placebo, ixekizumab 80mg once every 2 weeks
(IXEQ2W), ixekizumab 80mg once every 4 weeks
(IXEQ4W), or adalimumab 40mg Q2W (SPIRIT-P1 only;
not reported here). Both ixekizumab regimens included a
160-mg starting dose. At week 16, inadequate response
(defined by blinded, predefined criteria of < 20% improve-
ment from baseline in both tender joint counts [TJC] and
25 swollen joint counts [SJC]) was required to add or
modify concomitant medications. Patients in the placebo
group who were inadequate responders at week 16 were
given rescue therapy (including conventional disease-
modifying antirheumatic drugs [DMARDS], nonsteroidal
anti-inflammatory drugs, oral corticosteroids) and were
randomized to ixekizumab (IXEQ2W or IXEQ4W) and
continued ixekizumab for the remainder of the study.
Likewise, inadequate responders who were initially ran-
domized to ixekizumab received rescue therapy and con-
tinued with the initial ixekizumab regimen. SPIRIT-P1
and SPIRIT-P2 have similar study designs, with some ex-
ceptions; in SPIRIT-P1, patients were biologic-naive,
whereas in SPIRIT-P2, patients were experienced with
conventional DMARDs and biologic DMARDs.
These trials were compliant with ethical guidelines in-
cluding the Declaration of Helsinki and other relevant
laws and regulations. The protocols were approved by
each site’s ethical review committee/institutional review
board and all patients provided written informed consent.
Assessments
Enthesitis was assessed by the presence or absence of
tenderness at the 6 sites of the Leeds Enthesitis Index
(LEI), lateral epicondyle (left and right), medial femoral
condyle (left and right), and Achilles tendon insertion
(left and right) [15]. The absence (score = 0) or presence
(score = 1) at each of 6 sites is determined; results from
the 6 sites are then added to produce an LEI total score
ranging from 0 to 6.
Dactylitis was assessed by the Leeds Dactylitis
Index-Basic (LDI-B) [16, 17]. Scores based on the cir-
cumference and tenderness (presence or absence) of af-
fected digits were calculated and only acute (tender)
dactylitis was counted. The results of each digit are then
added to produce a total score.
Physical function and health-related quality of life
(HRQoL) were assessed by the Health Assessment Ques-
tionnaire Disability Index (HAQ-DI) [18, 19] and 5-level
EuroQol-5 Dimensions (EQ-5D 5L) instrument, respect-
ively [20]. Patient global assessment (PtGA) [21] and
pain visual analogue scale (VAS) were used to assess dis-
ease activity and pain intensity, respectively [22]. The
HAQ-DI is scored on a scale of 0 (no functional impair-
ment) to 3 (complete impairment) [23]; the minimal
clinically important difference (MCID) is estimated to be
an improvement from baseline of 0.35 [24]. The PtGA
and pain VAS are scored on a scale of 0–100 mm, in
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which higher scores represent more disease activity or
pain intensity, respectively [21, 22]. The EQ-5D com-
prises a VAS (0–100 scale in which 0 = worst health you
can imagine and 100 = best health you can imagine) as
well as the EQ-5D descriptive system, which includes 5
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression) measured in 5 levels ran-
ging from 1 = no problems to 5 = extreme problems.
Responses to the EQ-5D dimensions can be used to ob-
tain a single index value, with a range from 1 = full
health to 0 = dead [20].
Statistical analyses
The presence of enthesitis and dactylitis was defined as
LEI > 0 and LDI-B > 0, respectively, at baseline. Reso-
lution of enthesitis and dactylitis was defined as LEI = 0
and LDI-B = 0, respectively.
Integrated analyses of the placebo, IXEQ2W, and
IXEQ4W groups were performed using data from both
SPIRIT-P1 and SPIRIT-P2 trials. An integrated analysis
of adalimumab could not be performed because only
SPIRIT-P1 had an adalimumab group. Missing data (and
data from inadequate responders from week 16 to week
24) were considered as nonresponse for categorical mea-
sures (nonresponder imputation [NRI]) or imputed with
last observation carried forward (LOCF) method for
continuous measures. Comparisons between placebo
and ixekizumab treatment groups were performed with
a logistic regression model using Wald’s test with treat-
ment and study as factors. In post hoc analyses, associa-
tions between HAQ-DI or EQ-5D and enthesitis or
dactylitis were based on an analysis of covariance model,
adjusting for Disease Activity in PSoriatic Arthritis
(DAPSA) change from baseline (LOCF), study, and
LDI-B = 0 or LEI = 0 in the model. DAPSA is comprised
of SJC + TJC + PtGA + patient pain + C-reactive protein
[mg/dL]) [25, 26]. Change from baseline (LOCF) in pain
was summarized using mean and standard deviation by
patients’ enthesitis/dactylitis resolution status at week 24.
Results
Patients and disease burden at baseline
The integrated analysis set comprised 679 patients. At
baseline, 60% (n = 403 of 675) had enthesitis (LEI > 0)
and 23% (n = 155 of 676) had dactylitis (LDI-B > 0). Ta-
bles 1 and 2 show the baseline characteristics of patients
Table 1 Demographic and baseline characteristics (all treatment groups combined)
Characteristic LEI > 0
(N = 403)
LDI-B > 0
(N = 155)
Integrated analysis set
(N = 679)
Age, mean years (SD)a 51.2 (11.8) 47.8 (12.1) 51.0 (11.9)
Gender, n (%)
Male 166 (41.2) 70 (45.2) 310 (45.7)
Race, n (%)a
White 379 (94.0) 142 (91.6) 629 (92.8)
Black or African American 1 (0.2) 0 (0.0) 3 (0.4)
Asian 16 (4.0) 12 (7.7) 33 (4.9)
Other/multiple 7 (1.7) 1 (0.6) 13 (1.9)
BMI, kg/m2, mean (SD)a 31.2 (7.8) 29.9 (7.3) 30.2 (7.3)
cDMARD experience, n (%) 231 (57.3) 96 (61.9) 385 (56.7)
MTX at baseline, n (%) 192 (47.6) 81 (52.3) 318 (46.8)
Time since PsA onset, mean years (SD) 11.0 (8.8) 9.7 (8.0) 11.0 (9.3)
Active PSO with BSA ≥ 3%, n (%)a 241 (65.7) 105 (74.5) 402 (65.4)
Tender joint count (68 joints), mean (SD)a 25.2 (15.5) 22.2 (13.5) 22.0 (14.9)
Swollen joint count (66 joints), mean (SD)a 12.5 (9.1) 15.2 (11.3) 11.9 (9.1)
Current enthesitis, n (%)a 403 (100.0) 108 (69.7) 403 (59.7)
Current dactylitis, n (%)a 108 (26.8) 155 (100.0) 155 (22.9)
Leeds Enthesitis Index, mean (SD)a,b 2.9 (1.6) 3.1 (1.6) 2.9 (1.6)
Leeds Dactylitis Index-Basic, mean (SD)a,c 58.2 (72.0) 56.4 (68.3) 56.4 (68.3)
Abbreviations: BSA body surface area, BMI body mass index, cDMARD conventional disease-modifying antirheumatic drugs, LDI-B Leeds Dactylitis Index-Basic,
LEI Leeds Enthesitis Index, MTX methotrexate, N population size, n number in group, PsA psoriatic arthritis, PSO psoriasis, SD standard deviation
aThere are patients with missing baseline information in some groups; the denominator of a particular baseline measure is the number of patients with
non-missing baseline measures
bSummarized by patients with baseline enthesitis, defined as LEI score > 0
cSummarized by patients with baseline dactylitis, defined as LDI-B score > 0
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with enthesitis or dactylitis and of all patients within the
integrated analysis set.
Among patients with baseline enthesitis, the mean
(SD) baseline TJC was slightly higher (25.2 ± 15.5) com-
pared to the overall population (22.0 ± 14.9), whereas the
baseline SJC was similar to the overall population (12.5
± 9.1 and 11.9 ± 9.1, respectively). Among patients with
baseline dactylitis, baseline TJC was similar to the overall
population (22.2 ± 13.5 and 22.0 ± 14.9, respectively)
whereas baseline SJC scores were higher than the overall
population (15.2 ± 11.3 and 11.9 ± 9.1, respectively); the
percentage of patients with a baseline body surface area
of psoriasis ≥ 3% was higher than the overall population
(74% [n = 105 of 141] and 65% [n = 402 of 615], respect-
ively) (Table 1). Among patients with either enthesitis or
dactylitis, the mean baseline HAQ-DI score was 1.3,
which was similar to the burden in the overall popula-
tion (Table 2).
Among patients with enthesitis (n = 389) or dactylitis
(n = 151) and non-missing data at baseline, approxi-
mately 80% reported moderate, severe, or extreme scores
for the pain/discomfort domains of the EQ-5D 5L. Like-
wise, approximately 45 to 51% of patients reported mod-
erate, severe, or extreme scores for the mobility and
usual activities domains. (Additional file 1).
Resolution of enthesitis or dactylitis at week 24
Significantly higher proportions of IXEQ4W (39%)- and
IXEQ2W (35%)-treated patients with enthesitis at base-
line experienced resolution of enthesitis at week 24 than
placebo (21%) (Fig. 1a) in the integrated data set. While
results for the adalimumab arm in SPIRIT-P1 were not
included in the integrated analyses, 19% (placebo), 33%
(adalimumab, P = 0.073), 43% (IXEQ4W, P = 0.005), and
39% (IXEQ2W, P = 0.025) of patients with baseline
enthesitis experienced resolution of enthesitis at week 24
[13] in that trial. Likewise, in the integrated dataset, for
the lateral epicondyles, medial femoral condyles, and
Achilles tendon insertion sites, significantly higher pro-
portions of IXEQ4W-treated patients experienced
complete resolution of enthesitis than placebo-treated
patients (Fig. 1a). Additional file 2 shows enthesitis reso-
lution of the individual sites of all treatment groups, in-
cluding adalimumab in SPIRIT-P1.
Significantly higher proportions of IXEQ4W (78%)- and
IXEQ2W (65%)-treated patients with dactylitis at baseline
experienced resolution of dactylitis at week 24 than pla-
cebo (24%) (Fig. 1b). While results for the adalimumab
arm in SPIRIT-P1 were not included in the integrated ana-
lyses, 25% (placebo), 78% (adalimumab, P = 0.001), 80%
(IXEQ4W, P < 0.001), and 77% (IXEQ2W, P < 0.001) of
patients with baseline dactylitis experienced resolution of
dactylitis at week 24 in that trial [13].
Among patients who did not have dactylitis (LDI = 0)
or enthesitis (LEI = 0) at baseline, numerically more pla-
cebo patients had a post-baseline LEI > 0 or LDI > 0
than those patients receiving ixekizumab. Among 514
patients with LDI = 0 at baseline, 8/108 (7.4%) patients
on placebo had an LDI > 0 at week 24 vs 1/124 (0.8%)
on IXEQ4W and 2/142 (1.4%) on IXEQ2W. In the pla-
cebo group, 80/180 (44.4%) patients had LDI > 0 at any
time post-baseline vs 34/157 (21.7%) on IXEQ4W or 37/
177 (20.9%) on IXEQ2W. Among 271 patients with LEI
= 0 at baseline, 11/58 (19.0%) on placebo had LEI > 0 at
week 24 vs 6/76 (7.9%) on IXEQ4W or 6/69 (8.7%) on
IXEQ2W. In the placebo group, 50/97 (51.5%) had an
LEI > 0 at any time post-baseline vs 23/93 (24.7%) on
IXEQ4W or 18/81 (22.2%) on IXEQ2W.
Association of resolution of enthesitis or dactylitis with
improvement in disability and quality of life
At week 24, resolution of enthesitis symptoms was asso-
ciated with improvements in patients’ HRQoL (EQ-5D)
and function (HAQ-DI), with a larger proportion of
Table 2 Disease burden at baseline (all treatment groups combined)
Characteristic, mean (SD) LEI > 0
(N = 403)a
LDI-B > 0
(N = 155)a
Integrated analysis set
(N = 679)
Pt assessment of joint pain, mm n = 392
63.7 (19.7)
n = 151
66.9 (20.7)
n = 665
61.4 (21.1)
PtGA of disease activity, mm n = 392
64.6 (20.9)
n = 151
68.6 (21.1)
n = 665
63.9 (20.8)
HAQ-DI total score n = 391
1.3 (0.6)
n = 151
1.3 (0.7)
n = 664
1.2 (0.6)
EQ-5D 5L n = 389
0.6 (0.2)
n = 151
0.5 (0.2)
n = 661
0.6 (0.2)
EQ-5D VAS n = 389
52.5 (19.8)
n = 151
52.6 (21.9)
n = 661
54.1 (20.9)
Abbreviations: EQ-5D 5L EuroQoL-5 Dimensions 5 level, HAQ-DI Health Assessment Questionnaire-Disability Index, N number of patients in analysis population,
n number of patients with non-missing data, Pt patient, PtGA patient global assessment, VAS visual analogue scale
aBaseline enthesitis defined as a baseline LEI score > 0 and baseline dactylitis defined as a baseline LDI-B score > 0
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patients meeting the MCID for HAQ-DI change from
baseline than patients without resolution (Fig. 2a–c). In
addition, patients who resolved enthesitis had less pain
at week 24 than patients without resolution (Fig. 2d). At
week 24, resolution of dactylitis symptoms was associ-
ated with a greater proportion of patients meeting
MCID in HAQ-DI change from baseline than without
resolution, but smaller numerical improvements in pa-
tient function and HRQoL than patients resolving/not
resolving enthesitis (Fig. 2a–c). Resolution of dactylitis
was associated with improvements in patient-reported
pain at week 24 (Fig. 2d).
Discussion
PsA is a heterogeneous disease, with enthesitis and dac-
tylitis as manifestations for many patients. In this cohort,
60% of patients had enthesitis and 23% of patients had
dactylitis at baseline, consistent with published estimates
of 24 to 83% for enthesitis, but somewhat lower than
published estimates of 32 to 48% for dactylitis [5–7]. In
this integrated analysis of SPIRIT-P1 and SPIRIT-P2,
ixekizumab-treated patients with enthesitis or dactylitis
at baseline experienced greater resolution in their enthe-
sitis or dactylitis compared to placebo at week 24. We
further found that resolution of these manifestations
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were associated with improvements in function and
HRQoL, irrespective of treatment. Patients who had
resolution of their enthesitis/dactylitis symptoms also
experienced less pain.
In patients with enthesitis and dactylitis, patient-re-
ported pain and PtGA at baseline were slightly higher than
the overall population, whereas HAQ-DI and EQ-5D 5L
and VAS were similar to the overall population. Our ana-
lyses did not compare baseline disease burden between
patients with vs without enthesitis or with vs without dac-
tylitis; however, recent real-world evidence has shown a
greater disease burden in patients with, relative to patients
without, enthesitis [9, 27, 28]. Using data from the Univer-
sity of Toronto PsA cohort [27], Polachek et al. demon-
strated that patients with enthesitis, as measured by the
Spondyloarthritis Research Consortium of Canada
(SPARCC) enthesitis index, compared to patients without
enthesitis had a higher actively inflamed joint count (odds
ratio [OR] 1.06, P = 0.0002), presence of dactylitis (OR 2.5,
P = 0.02), presence of tenosynovitis (OR 5.3, P < 0.0001),
and more pain (OR 1.15, P = 0.01). Similarly, in a retro-
spective, cross-sectional study from the Consortium of
Rheumatology Researchers of North America PsA/Spon-
dyloarthritis Registry [9], patients with enthesitis, as mea-
sured by the SPARCC, had higher overall work/activity
impairment, patient-reported pain, and fatigue compared
with patients without enthesitis; however, patients with
dactylitis, compared to those without dactylitis, were less
impacted based on overall work/activity impairment, pain,
and fatigue relative to patients with enthesitis. Differences
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between real-world evidence and the data presented here
may reflect differences in populations enrolled in clinical
trials compared to those in the real world.
We did observe that patients whose enthesitis resolved
had twice the improvement in quality of life (EQ-5D)
compared to patients with residual enthesitis. Pain also
improved by more than 2-fold compared to patients who
had residual enthesitis symptoms. Greater improvement
in functional ability (HAQ-DI) was also seen in patients
with resolution of enthesitis vs those with residual enthe-
seal symptoms, and notably more than double the per-
centage of patients with resolution of enthesitis reported
clinically meaningful changes in HAQ-DI compared to
patients with unresolved enthesitis. Resolution of dactylitis
was associated with smaller improvements relative to
enthesitis resolution based on mean change from baseline
of HAQ-DI and EQ-5D scores. Similar to the enthesitis
analysis, a higher percentage of patients with dactylitis
resolution reported clinically meaningful changes in
HAQ-DI compared to patients with unresolved dactylitis
and percentages of patients with/without dactylitis were
similar to those of patients with/without enthesitis; there
were also improvements in pain.
The ability to see an association of improvement in
physical functioning and quality of life with dactylitis
resolution may be limited due to the smaller numbers of
patients with dactylitis than enthesitis. Additionally, the
model adjusted for DAPSA, which includes a measure of
TJC and SJC; the adjustment for joint activity may have
confounded analysis of association between dactylitis
and functioning/quality of life. The association between
dactylitis and HRQoL is inconsistent in literature [9, 28].
Anecdotally, based on personal patient observations
made by the authors, patients with dactylitis may not be
as symptomatic as patients with enthesitis. Pain was only
summarized (i.e., without adjustment for DAPSA) be-
cause pain is a component of DAPSA.
Despite the challenges in assessment of enthesitis,
we did observe significant treatment effects with ixeki-
zumab for the LEI total score as well as at the individ-
ual sites comprising the index (lateral epicondyle,
medial femoral condyle, Achilles tendon insertion).
Several factors can increase the inter-observer variabil-
ity of the assessment of enthesitis, such as the identifi-
cation of the entheseal points, the intensity of the
pressure applied, the patient’s pain threshold level, or
the presence of other conditions that also cause pain
(e.g., fibromyalgia) [5, 29]. Of note, numerically, the
largest differences between ixekizumab and placebo in
the resolution of enthesitis were observed at the Achil-
les tendon insertion. This site may be the most reliable
site for detecting treatment effects in clinical trials due
to the lack of overlap with the tender points of fibro-
myalgia [30], which can confound its assessment.
Additionally, it should be noted that the LEI limits de-
tection to 6 sites, whereas other enthesitis indices
measure more sites.
While these results indicate that ixekizumab is ef-
fective for the treatment of enthesitis and dactylitis,
the SPIRIT studies were not designed to evaluate
enthesitis and dactylitis as primary endpoints. Add-
itionally, patients in SPIRIT-P1 and SPIRIT-P2 were
not randomized based on enthesitis or dactylitis,
enthesitis or dactylitis were not required at entry, nor
was a specific symptom threshold specified; inadequate
responders were defined based on tender and swollen
joint counts. As expected, some patients on placebo
who received background medications experienced
resolution of dactylitis or enthesitis consistent with
published data [27].
Future studies of enthesitis could utilize imaging
techniques that can measure pathology such as
ultrasound and whole body MRI, which are being
investigated [5, 29, 31]. The Outcome Measures in
Rheumatology Ultrasound Task Force recently
attempted to define enthesitis using ultrasound and in-
cluded hypoechogenicity, increased thickness of the
tendon insertion, calcifications, enthesophytes, ero-
sions, and Doppler activity as core lesions of
ultrasound-detected enthesitis, but this work is not
fully validated [32]. GRAPPA is also attempting to de-
velop an imaging index for enthesitis [33, 34].
Conclusions
Treatment with ixekizumab every 2 weeks and every 4
weeks resulted in significant improvements in enthesitis
and dactylitis in patients with pre-existing enthesitis or
dactylitis. Resolution of enthesitis symptoms was associ-
ated with improvements in patients’ function, pain, and
HRQoL, irrespective of treatment.
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